Codexis has been granted a patent for engineered galactose oxidase enzymes, polypeptides, and polynucleotides, along with methods for their production. The invention is aimed at producing pharmaceutical and other compounds efficiently. GlobalData’s report on Codexis gives a 360-degree view of the company including its patenting strategy. Buy the report here.
According to GlobalData’s company profile on Codexis, Bioethanol production GMOs was a key innovation area identified from patents. Codexis's grant share as of May 2024 was 27%. Grant share is based on the ratio of number of grants to total number of patents.
A recently granted patent (Publication Number: US12012618B2) discloses an engineered galactose oxidase with specific polypeptide sequences and substitutions, resulting in enhanced production of 2-ethynylglyceraldehyde with increased enantiomeric excess of the R-stereoisomer compared to the wild-type F. graminearium galactose oxidase. The engineered galactose oxidase includes substitutions at key positions in the polypeptide sequence, such as 291, 375, 453, and 465, leading to improved enzymatic activity.
Moreover, the patent covers variants of the engineered galactose oxidase with specific sequence identities to SEQ ID NOS: 1598, 1866, 1912, 2080, 2300, and/or 2424. These variants exhibit similar substitutions at various amino acid positions, enhancing the catalytic properties of the enzyme. The patent also includes claims for purified engineered galactose oxidase and compositions containing this modified enzyme, highlighting its potential applications in biocatalysis and industrial processes requiring selective oxidation reactions.
To know more about GlobalData’s detailed insights on Codexis, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.